Skip to main content

Comprehensive Cancer Panel for Tumor Profiling

Cancer is a complex disease characterized by uncontrolled cell growth and the accumulation of genetic alterations. Understanding the genomic landscape of tumors is crucial for accurate diagnosis, treatment selection, and monitoring of cancer patients. In the quest to unravel the complex genetic landscape of cancer, a breakthrough technology has emerged: the Comprehensive Cancer Panel.

This advanced genomic tool provides an all-encompassing approach to tumor profiling, offering a comprehensive analysis of genetic alterations implicated in various cancer types. It has advantages over individual biomarker assays in its ability to detect multiple biomarkers with one test, saving time, money and samples. The comprehensive cancer panel employs next-generation sequencing (NGS) to target 523 genes in different tumor types. Not only does this assay identify all relevant variants (SNVs, insertions, deletions and CNVs) across various tumor types, but it also reports tumor mutational burden (TMB) and microsatellite instability (MSI) scores.​

The design of a comprehensive cancer panel is a meticulous process that involves the selection of genes and genomic regions crucial to underlying biology of cancer, such as critical biomarkers with known cancer associations as indicated in drug labels, European Society for Medical Oncology (ESMO) recommendations, and information shared on clinical trials for solid tumor types. The panel cover a wide range of oncogenes, tumor suppressor genes, DNA repair genes, and other key elements implicated in cancer development and progression, offering comprehensive genomic profiling across various malignancies, including solid tumor (breast, lung, bone, colorectal, prostate, ovarian, and pancreatic cancer), neurological tumors (CNS cancer), genitourinary tumors (kidney and bladder cancer), skin cancers (melanoma), and others (Table 1).

Table 1. Comprehensive Cancer Panel biomarkers.

Advantages of the comprehensive cancer panel

Comprehensive Coverage

The extensive gene content covers a wide array of oncogenes, tumor suppressor genes, and other clinically relevant markers, enabling a holistic view of the genetic landscape of various tumor types.

Multitumor Profiling

The panel is designed to analyze a diverse range of tumor types, allowing clinicians and researchers to gain insights into different malignancies using a single test.

Low-frequency Variants / Highly Sensitive

The comprehensive panel can detect low-frequency genetic alterations, including subclonal mutations and minor subpopulations within the tumor. This capability is particularly valuable in capturing the heterogeneity of tumors, identifying minor clones with potential implications for treatment response and disease progression.


By considering the combination of comprehensive genomic profiling, precision insights, streamlined workflows, and the potential for cost savings in treatment decisions and resource management, the panel offers a cost-effective solution that aligns with the evolving landscape of oncology diagnostics and research.

Precision Insights

By identifying genetic alterations, mutations, and variations, the cancer panel enables precise identification of driver mutations and actionable biomarkers, facilitating personalized treatment decisions.

Reduced Sample Requirements

The efficient library preparation techniques enable reliable results even with limited sample quantities, which is especially valuable in cases where obtaining larger samples is challenging.


The detailed and customizable reports that present genetically relevant information in a clear and concise manner, aiding clinicians in making informed decisions.

The workflow of comprehensive profiling

The workflow of comprehensive cancer panel analysis involves several key steps. Initially, tumor tissue is collected from the patient through a biopsy or surgical procedure. If requested, the biopsy sample undergoes a pathology to determine the tumor cell percentage before DNA extraction, healthcare professionals can better tailor genetic testing approaches and make more informed decisions regarding patient treatment and management. Genetic material (DNA) is extracted from the tumor tissue and proceed to library preparation. This involves DNA fragmentation, attaching molecular tags, and preparation for sequencing. The libraries are subjected to NGS using cutting-edge sequencing platforms, such as Illumina, generating vast amounts of sequencing data. Advanced bioinformatics pipelines are employed to process and analyze the data, identifying genetic alterations within the targeted genomic regions. Annotation databases and bioinformatics tools aid in interpreting the detected alterations, providing crucial insights into potential driver mutations, therapeutic targets, and prognostic markers (Figure 1).

Cancer panel workflow Comprehensive Cancer Panel for Tumor Profiling

Figure 1. Comprehensive Cancer Panel workflow.

In conclusion, the comprehensive cancer panels are revolutionizing the field of cancer diagnostics, ushering in an era of precision medicine. The genetic profiling of tumors empowers clinicians to unravel the distinct genetic composition of each patient’s cancer, thereby paving the way for tailored treatment strategies. This innovative approach not only permits the identification of precise therapeutic options but also offers the opportunity to match patients with targeted therapies and clinical trials tailored to the specific genetic aberrations detected in their tumors. By aligning treatment choices with the unique genetic makeup of each cancer, this paradigm shift significantly amplifies the prospects of treatment efficacy and elevates patient outcomes to new heights.

Service specifications

We have summarized key information about our Comprehensive Cancer Panel solution into a service specification sheet. You can download this by clicking on the image.

Let’s connect!

dr. Stefanie Klaver-Flores, our Head of Oncology is ready to support your workflows with our oncology solutions. You can reach out to her by sending email to

Stefanie Klaver Flores square Comprehensive Cancer Panel for Tumor Profiling

About GenomeScan

GenomeScan is a leading provider in the context of Unveiling the Genetic Landscape of Cancer. With our state-of-the-art technologies, we provide a deep and detailed analysis of the genetic landscape underlying various cancer types, targeting genes and genomic regions known to be associated with cancer development and progression, ensuring a thorough assessment of the tumor genome. Leveraging state-of-the-art next-generation sequencing technologies and advanced bioinformatics analysis, we uncover critical genetic alterations, including mutations, copy number variations, and structural variants. With a focus on accuracy, reliability, and personalized support, GenomeScan empowers researchers and clinicians to make informed decisions in diagnosis, treatment selection, and patient management, ultimately driving advancements in precision oncology.

Leave a Reply